Climb Bio (CLYM) Cash from Financing Activities (2020 - 2026)
Climb Bio's (CLYM) quarterly Cash from Financing Activities came in at $5000.0 in Q1 2026, up 123.81% on a QoQ basis from -$21000.0 in Q4 2025.
Climb Bio (CLYM) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 6 years of Cash from Financing Activities data on file, last reported at $5000.0 in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16000.0 (down 100.01% YoY) and the FY2025 annual result came in at -$21000.0, down 100.02% from the prior year.
- Cash from Financing Activities grew to $5000.0 in Q1 2026, from -$21000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $128.4 million in Q2 2024 to a low of -$21000.0 in Q4 2025.
- A 4-year average of $13.2 million and a median of $32500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 534908.33% — and 2025, when it plunged 151.22%.
- Tracing CLYM's Cash from Financing Activities over 4 years: stood at $288000.0 in 2023, then slumped by 85.76% to $41000.0 in 2024, then sank by 151.22% to -$21000.0 in 2025, then surged by 123.81% to $5000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $5000.0 (Q1 2026), -$21000.0 (Q4 2025), and $41000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 103.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.70 Mn |
| Jun 30, 2026 | 103.70 Mn |
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | -21,000.00 |
| Dec 31, 2025 | -21,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 2.27 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 128.40 Mn |
| Jun 30, 2024 | 128.40 Mn |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 528,000.00 |
| Sep 30, 2023 | 528,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 24,000.00 |